September 6, 2026 · Phase 3 readout
ALK-B.CO Phase 3 readout: a neutral outcome, +0.0%
On September 6, 2026, HDM SLIT-tablet (12 SQ-HDM) — ALK-Abelló A/S (Allergic Rhinoconjunctivitis) reached its Phase 3 readout. The result was a neutral outcome, and the stock moved +0.0% in the window around the event. It had already run -6.6% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$208.80
1d before
$208.80
Event day
$206.00
1d after
$195.90
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.0% expected); the stock actually moved +0.0%. Model confidence at the time: 95%.
See the full scored track recordPre-catalyst setup
-6.6%
30-day run-up
2978%
30-day volatility
0.6×
volume spike